Quinazoline derivatives as tyrosine kinase inhibitors

Details for Australian Patent Application No. 2004272350 (hide)

Owner AstraZeneca AB

Inventors Kettle, Jason Grant; Bradbury, Robert Hugh; Barlaam, Bernard Christope; Hennequin, Laurent Francois Andre

Agent Davies Collison Cave

Pub. Number AU-A-2004272350

PCT Pub. Number WO2005/026151

Priority 03292279.1 16.09.03 EP

Filing date 14 September 2004

Wipo publication date 24 March 2005

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61P 35/00 (2006.01) Antineoplastic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/026151 Priority application(s): WO2005/026151

4 June 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272351-Quinazoline derivatives as antitumor agents

2004272348-Quinazoline derivatives as tyrosine kinase inhibitors